Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although it has long been appreciated that ovarian carcinoma subtypes (serous, clear cell, endometrioid, and mucinous) are associated with different natural histories, most ovarian carcinoma biomarker studies and current treatment protocols for women with this disease are not subtype specific. With the emergence of high-throughput molecular techniques, distinct pathogenetic pathways have been identified in these subtypes. We examined variation in biomarker expression rates between subtypes, and how this influences correlations between biomarker expression and stage at diagnosis or prognosis. METHODS AND FINDINGS: In this retrospective study we assessed the protein expression of 21 candidate tissue-based biomarkers (CA125, CRABP-II, EpCam, ER, F-Spondin, HE4, IGF2, K-Cadherin, Ki-67, KISS1, Matriptase, Mesothelin, MIF, MMP7, p21, p53, PAX8, PR, SLPI, TROP2, WT1) in a population-based cohort of 500 ovarian carcinomas that was collected over the period from 1984 to 2000. The expression of 20 of the 21 biomarkers differs significantly between subtypes, but does not vary across stage within each subtype. Survival analyses show that nine of the 21 biomarkers are prognostic indicators in the entire cohort but when analyzed by subtype only three remain prognostic indicators in the high-grade serous and none in the clear cell subtype. For example, tumor proliferation, as assessed by Ki-67 staining, varies markedly between different subtypes and is an unfavourable prognostic marker in the entire cohort (risk ratio [RR] 1.7, 95% confidence interval [CI] 1.2%-2.4%) but is not of prognostic significance within any subtype. Prognostic associations can even show an inverse correlation within the entire cohort, when compared to a specific subtype. For example, WT1 is more frequently expressed in high-grade serous carcinomas, an aggressive subtype, and is an unfavourable prognostic marker within the entire cohort of ovarian carcinomas (RR 1.7, 95% CI 1.2%-2.3%), but is a favourable prognostic marker within the high-grade serous subtype (RR 0.5, 95% CI 0.3%-0.8%). CONCLUSIONS: The association of biomarker expression with survival varies substantially between subtypes, and can easily be overlooked in whole cohort analyses. To avoid this effect, each subtype within a cohort should be analyzed discretely. Ovarian carcinoma subtypes are different diseases, and these differences should be reflected in clinical research study design and ultimately in the management of ovarian carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“The dismal response rate of clear cell carcinomas (15%) contrasts sharply with that of high-grade serous (80%), resulting in a lower 5-y survival for clear cell compared with high-grade serous carcinoma in patients with advanced stage tumors (20% versus 30%) [7,8].”
BackgroundWright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040 · cited 1×
“, breast carcinoma and lymphoma [24,25]), and this subtype specific approach to treatment has implications for the design of clinical trials for women with ovarian carcinomas.”
BackgroundGrading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670 · cited 1×
“The serous subtype was further subdivided into low- and high-grade [11].”
BackgroundLu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0409 · Cited by 440 · cited 1×
“For example, CA125 is expressed in most high-grade serous carcinoma, but only in 60% of mucinous and clear cell subtypes, a finding that is consistent with previous studies [26].”
ResultSchwartz, D. R., Kardia, S. L. R., Shedden, K., Kuick, R. D., Michailidis, G. C., Taylor, J. M. G., Misek, D. E., WU, R. T., Zhai, Y., Darrah, D. M., et al. (2002) · PubMed · Cited by 430
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408 · cited 1×
“The goal of our marker selection was to use proteins that are consistently expressed in ovarian carcinomas and have been reported as prognosticators (p53, p21, Ki-67, PR, WT1) [”
MethodZorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376 · cited 1×
“Each of theses subtypes is associated with different genetic risk factors and molecular events during oncogenesis [1,2], and characterized by distinct mRNA expression profiles [3,4].”
Background
Research works printed but not linked: 2
- Swenerton KD 2008 Ovarian carcinoma treatment guidelines of the British Columbia Cancer Agency Available: http://www.bccancer.bc.ca/PPI/TypesofCancer/Ovary/default.htm. Accessed 1 April 2000
- Turbin DA Leung S 2008 GPEC plugin for Image J an image analyzing software Available: http://www.gpec.ubc.ca/index.php?content=software/imagej_plugin/index.php. Accessed 20 April 2008
Cited by
International Statistical Classification of Diseases and Related Health Problems
Eisfeld, J. (2014) · TSQ: Transgender Studies Quarterly · doi:10.1215/23289252-2399740 · Cited by 3,570
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Self-citationRethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3144 · Cited by 1,464
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
A clinically applicable molecular-based classification for endometrial cancers
Talhouk, A., McConechy, M. K., Leung, S., Li-Chang, H. H., Kwon, J. S., Melnyk, N., Yang, W., Senz, J., Boyd, N., Karnezis, A. N., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.190 · Cited by 971
“This has been a game-changing approach in ovarian cancers (Kobel et al, 2008; Kurman and Shih Ie, 2011; Despierre et al, 2014) and has the potential to greatly advance progress in endometrial cancer research.”
BackgroundSelf-citationDriver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 787
“It has become increasingly clear that ovarian cancer is a series of distinctly different diseases with different aetiologies [23,37] and that the development of reliable biomarkers must be subtype-specific [38].”
BackgroundPrat, J. (2012) · Virchows Archiv · doi:10.1007/s00428-012-1203-5 · Cited by 602
“expression profile within a given type is consistent across stage [10].”
BackgroundCA125 and Ovarian Cancer: A Comprehensive Review
Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F. O., Narod, S. A., & Akbari, M. R. (2020) · Cancers · doi:10.3390/cancers12123730 · Cited by 602
“HGSC and endometroid ovarian cancers have a higher expression of CA125 compared to other subtypes [48].”
BackgroundA Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors
Laury, A. R., Perets, R., Piao, H., Krane, J. F., Barletta, J. A., French, C., Chirieac, L. R., Lis, R., Loda, M., Hornick, J. L., et al. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318216c112 · Cited by 460
“3B) and glandular (ACIS) lesions of the cervix (N=2 and 5, respectively) were moderately to strongly immunoreactive for PAX8.”
ResultInfluentialMilne, K., Köbel, M., Kalloger, S. E., Barnes, R. O., Gao, D., Gilks, C. B., Watson, P. H., & Nelson, B. H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006412 · Cited by 446
“We chose to first focus on high-grade serous cases, as the other histological subtypes exhibit distinct biological and clinical properties that are potentially confounding [54,55].”
BackgroundSelf-citationThe genesis and evolution of high-grade serous ovarian cancer
Bowtell, D. D. L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2946 · Cited by 445
Epithelial cell adhesion molecule expression (CD326) in cancer: A short review
Patriarca, C., Macchi, R. M., Marschner, A. K., & Mellstedt, H. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.04.002 · Cited by 434
“2).(30) A retrospective study in a population-based cohort of 500 ovarian carcinoma patients examined the variation in expression of 21 biomarkers in four histological subtypes (high-grade serous, clear cell, endometroid, and mucinous carcinoma) and at different stages of disease (FIGO stage I–III).”
BackgroundSieh, W., Köbel, M., Longacre, T. A., Bowtell, D. D., deFazio, A., Goodman, M. T., Høgdall, E., Deen, S., Wentzensen, N., Moysich, K. B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70253-5 · Cited by 433
Self-citationCheung, H. W., Cowley, G. S., Weir, B. A., Boehm, J. S., Rusin, S., Scott, J. A., East, A., Ali, L. D., Lizotte, P. H., Wong, T. C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109363108 · Cited by 423
“Previous studies using immunohistochemistry showed that 89–100% of serous, clear cell, and endometrioid subtypes and 8% of mucinous subtype express PAX8 (26).”
BackgroundHaslehurst, A. M., Koti, M., Dharsee, M., Nuin, P., Evans, K., Geraci, J., Childs, T., Chen, J., Li, J., Weberpals, J., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-91 · Cited by 402
“Of the gynecological malignancies, ovarian cancer has the highest associated mortality rate in the western world [1,2].”
BackgroundDifferences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas
Köbel, M., Kalloger, S. E., Huntsman, D. G., Santos, J. L., Swenerton, K. D., Seidman, J. D., & Gilks, C. B. (2010) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3181c042b6 · Cited by 398
“Biomarker expression correlates exquisitely with tumor type (5).”
BackgroundInfluentialSelf-citationOvarian Tumor Tissue Analysis (OTTA) Consortium, Goode, E. L., Block, M. S., Kalli, K. R., Vierkant, R. A., Chen, W., Fogarty, Z. C., Gentry-Maharaj, A., Toloczko, A., Hein, A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3290 · Cited by 394
Self-citationBiomarkers in Cancer Detection, Diagnosis, and Prognosis
Das, S., Dey, M. K., Devireddy, R., & Gartia, M. R. (2023) · Sensors · doi:10.3390/s24010037 · Cited by 383
Webb, J. R., Milne, K., Kroeger, D. R., & Nelson, B. H. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.03.008 · Cited by 335
Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution.
Oksa, P., Wolff, H. J., Vehmas, T., Pallasaho, P., & Frilander, H. (1997) · PubMed · Cited by 319
New insights into ovarian cancer pathology
Prat, J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds300 · Cited by 317
“CCCs are usually positive for HNF1-β (>90%) and are negative for ER and WT1 in >95% of cases [21, 30].”
BackgroundDriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer
Bashashati, A., Haffari, G., Ding, J., Ha, G., Lui, K., Rosner, J., Huntsman, D. G., Caldas, C., Aparicio, S. A., & Shah, S. P. (2012) · Genome Biology · doi:10.1186/gb-2012-13-12-r124 · Cited by 302
“Type I ovarian cancers exhibit considerably different expression profiles compared to Type II high-grade serous cancers [25].”
BackgroundSelf-citationMyungjin Lee, J., Mhawech-Fauceglia, P., Lee, N., Cristina Parsanian, L., Gail Lin, Y., Andrew Gayther, S., & Lawrenson, K. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.41 · Cited by 301
Ovarian Cancer Pathogenesis: A Model in Evolution
Karst, A. M., & Drapkin, R. (2010) · Journal of Oncology · doi:10.1155/2010/932371 · Cited by 298
“A recent immunohistochemical biomarker study of 500 ovarian carcinomas found that 20 of 21 candidate tumor biomarkers had significantly different expression patterns in each tumor subtype and that two thirds of the biomarkers lost their prognostic value when survival analyses were made subtype specific [66].”
BackgroundPrat, J., D'Angelo, E., & Espinosa, I. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.06.018 · Cited by 275
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
Wang, Y. K., Bashashati, A., Anglesio, M. S., Cochrane, D. R., Grewal, D. S., Ha, G., McPherson, A., Horlings, H. M., Senz, J., Prentice, L. M., et al. (2017) · Nature Genetics · doi:10.1038/ng.3849 · Cited by 273
Self-citationAnglesio, M. S., Carey, M. S., Köbel, M., MacKay, H., & Huntsman, D. G. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.01.005 · Cited by 272
“TP53 IHC rarely shows overexpression for p53 – presumed wild-type Sensor of DNA damage and apoptosis [2,32,34] 409 M.”
BackgroundSelf-citationOvarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria
Hauptmann, S., Friedrich, K., Redline, R., & Avril, S. (2017) · Virchows Archiv · doi:10.1007/s00428-016-2040-8 · Cited by 270
Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C., Prentice, L. M., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072162 · Cited by 253
“Presentation Presents at younger age and low stage (pelvic mass) [4,29–31] Presents at younger age (than HGSC) [4,29–31] Presents at younger age (than HGSC) [4,29–31] Histopathological similarity to gastric carcinomas (intestinal type) [1,8,31] Presents at younger age (than HGSC) [4,29–31] Presents at older age (than…”
BackgroundMethodSelf-citationOvarian carcinoma pathology and genetics: recent advances
Gilks, C. B., & Prat, J. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.04.017 · Cited by 249
“The different cell types of ovarian carcinoma (eg, serous, endometrioid, clear cell) are associated with different underlying molecular abnormalities, so that light microscopic examination alone can identify groups of tumors with different genetic alterations [3-8].”
BackgroundInfluentialSelf-citationThe Preclinical Natural History of Serous Ovarian Cancer: Defining the Target for Early Detection
Brown, P. O., & Palmer, C. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000114 · Cited by 246
“Clearly, it would be a mistake to assume that they apply to ovarian cancers of histological types other than serous; these are distinctly different diseases, clinically and molecularly [3,4].”
BackgroundSelf-citationClear cell carcinoma of the ovary: A review of the literature
del Carmen, M. G., Birrer, M., & Schorge, J. O. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.04.021 · Cited by 246
“CCC tumors have low levels of chromosomal instability and low proliferation rates, with high frequency of phosphoinositide 3-kinase catalytic alpha (PIK3CA mutations) [10,22,26,29].”
BackgroundLatifi, A., Luwor, R. B., Bilandzic, M., Nazaretian, S., Stenvers, K., Pyman, J., Zhu, H., Thompson, E. W., Quinn, M. A., Findlay, J. K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046858 · Cited by 240
Walton, J., Blagih, J., Ennis, D., Leung, E., Dowson, S., Farquharson, M., Tookman, L. A., Orange, C., Athineos, D., Mason, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1272 · Cited by 237
“PAX8 staining is used in the diagnosis of HGSC and is usually strongly positive, although this is not universal (30).”
BackgroundA Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer
Nagaraja, A. K., Creighton, C. J., Yu, Z., Zhu, H., Gunaratne, P. H., Reid, J. G., Olokpa, E., Itamochi, H., Ueno, N. T., Hawkins, S. M., et al. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0295 · Cited by 230
PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma
Laury, A. R., Hornick, J. L., Perets, R., Krane, J. F., Corson, J., Drapkin, R., & Hirsch, M. S. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181da7687 · Cited by 230
“Calretinin, CK5/6, D2-40, and WT1 are positive in more than 90% of mesotheliomas; however, they have also been shown to be expressed in approximately 10%, 25%, 65%, and 90% of serous ovarian carcinomas, respectively.(23) This study confirms the high sensitivity of PAX8 for ovarian serous neoplasms, as 253/254 (99.”
BackgroundInfluentialRisk Factors for Epithelial Ovarian Cancer by Histologic Subtype
Gates, M. A., Rosner, B. A., Hecht, J. L., & Tworoger, S. S. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwp314 · Cited by 227
Expression of PAX8 in Normal and Neoplastic Tissues: A Comprehensive Immunohistochemical Study
Tacha, D., Zhou, D., & Cheng, L. (2011) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0b013e3182025f66 · Cited by 226
An Immunohistochemical Algorithm for Ovarian Carcinoma Typing
Köbel, M., Rahimi, K., Rambau, P. F., Naugler, C., Le Page, C., Meunier, L., de Ladurantaye, M., Lee, S., Leung, S., Goode, E. L., et al. (2016) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000274 · Cited by 221
“Although almost all CCC and MC remain WT1 negative, WT1 expression in EC has also increased slightly from 4% (1) to 10% currently, which is similar to another study (28).”
BackgroundResultSelf-citationMass spectrometry-based proteomics as an emerging tool in clinical laboratories
Birhanu, A. G. (2023) · Clinical Proteomics · doi:10.1186/s12014-023-09424-x · Cited by 220
“For example, several studies have shown over 30 different of ovarian cancer subtypes, each of which arise from a different cell and has its own unique proteome [258–260].”
BackgroundHelland, Å., Anglesio, M. S., George, J., Cowin, P. A., Johnstone, C. N., House, C. M., Sheppard, K. E., Etemadmoghadam, D., Melnyk, N., Rustgi, A. K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018064 · Cited by 215
“It is increasingly apparent that ovarian cancer is a complex series of distinct tumour types [1], requiring therapies that target molecular features common to the subtypes of the disease.”
BackgroundSelf-citationEvolution of platinum resistance in high-grade serous ovarian cancer
Cooke, S. L., & Brenton, J. D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70123-1 · Cited by 213
Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy
Gugnoni, M., Sancisi, V, Gandolfi, G., Manzotti, G., Ragazzi, M., Giordano, D., Tamagnini, I., Tigano, M., Frasoldati, A., Piana, S., et al. (2017) · Oncogene · doi:10.1038/onc.2016.237 · Cited by 213
Preston, C. C., Maurer, M. J., Oberg, A. L., Visscher, D. W., Kalli, K. R., Hartmann, L. C., Goode, E. L., & Knutson, K. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080063 · Cited by 208
“Delineation of the role of Tregs or other lymphocyte populations in ovarian cancer in the future will likely have to account for differences in biology and importantly, survival times among the different histologic subtypes [44].”
BackgroundAntibody-based proteomics: fast-tracking molecular diagnostics in oncology
Brennan, D. J., O'Connor, D. P., Rexhepaj, E., Ponten, F., & Gallagher, W. M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2902 · Cited by 208
Ferraro, S., Braga, F., Lanzoni, M., Boracchi, P., Biganzoli, E. M., & Panteghini, M. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201031 · Cited by 198
Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer
Suryawanshi, S., Vlad, A. M., Lin, H.-M., Mantia-Smaldone, G., Laskey, R., Lee, M., Lin, Y., Donnellan, N., Klein-Patel, M., Lee, T., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2726 · Cited by 197
“Ovarian cancer is a highly heterogeneous disease and the 4 main histologic subtypes of ovarian cancer are now considered different diseases, which may develop differently, respond differently to chemotherapy, and express different sets of biomarkers (38).”
Mucinous Tumors of the Ovary: Current Thoughts on Diagnosis and Management
Brown, J., & Frumovitz, M. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0389-x · Cited by 188
“Other differences have been identified in the matrix metalloproteinases, p53, cadherin, CA125, and WT-1, among others [60–62].”
BackgroundTumor evolution and chemoresistance in ovarian cancer
Kim, S., Han, Y., Kim, S. I., Kim, H.-S., Kim, S. J., & Song, Y. S. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0063-0 · Cited by 187
Schauer, I. G., Sood, A. K., Mok, S., & Liu, J. (2011) · Neoplasia · doi:10.1593/neo.101720 · Cited by 155
“Thus, specific genetic mutations among diverse histomorphologic ovarian cancer subtypes allow pathologists to identify and diagnose tumor specimens by microscopy [7,8].”
BackgroundMcAlpine, J. N., Porter, H., Köbel, M., Nelson, B. H., Prentice, L. M., Kalloger, S. E., Senz, J., Milne, K., Ding, J., Shah, S. P., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.211 · Cited by 185
Self-citationMcCluggage, W. G., Singh, N., & Gilks, C. B. (2022) · Histopathology · doi:10.1111/his.14609 · Cited by 184
“In the 4th edition, it was emphasised that the five main ovarian carcinoma histotypes (high-grade serous, low-grade serous, endometrioid, clear cell, and mucinous) differ with respect to risk factors, genetic events during oncogenesis, precursor lesions, immunophenotype, patterns of spread, response to chemotherapy, a…”
BackgroundSelf-citationEndometrial cancer: Not your grandmother's cancer
McAlpine, J. N., Temkin, S. M., & Mackay, H. J. (2016) · Cancer · doi:10.1002/cncr.30094 · Cited by 183
Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden
Anglesio, M. S., Bashashati, A., Wang, Y. K., Senz, J., Ha, G., Yang, W., Aniba, M. R., Prentice, L. M., Farahani, H., Li Chang, H., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4516 · Cited by 180
“As histotypes of ovarian cancer are now clearly acknowledged as distinct diseases [44], endometriosis is well recognized as a risk factor specific to clear cell and endometrioid types [5,6].”
BackgroundSelf-citationEstrogens and the risk of breast cancer: A narrative review of literature
Al‐Shami, K., Awadi, S., Khamees, A., Alsheikh, A. M., Al-Sharif, S., Bereshy, R., Al-Eitan, S. F., Banikhaled, S. H., Al-Qudimat, A. R., Al‐Zoubi, R. M., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20224 · Cited by 180
“Epithelial ovarian cancers are heterogeneous in their morphology, gene and protein expression [56 – 58].”
Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening
Häusler, S. F. M., Keller, A., Chandran, P. A., Ziegler, K., Zipp, K., Heuer, S., Krockenberger, M., Engel, J. B., Hönig, A., Scheffler, M., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605833 · Cited by 178
“Therefore, it might be desirable to establish specific miRNA fingerprints for the individual subtypes of OvCA rather than 697 British Journal of Cancer (2010) 103(5), 693 – 700& 2010 Cancer Research UK aiming at a general approach (Köbel et al, 2008).”
BackgroundBao, X., Zhao, S., Liu, T., Liu, Y., Liu, Y., & Yang, X. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413475452 · Cited by 174
“Different histologies of EOC have distinct pathogenetic profiles (Kobel et al. 2008).”
BackgroundThe Evolution of Ovarian Carcinoma Subclassification
Köbel, M., & Kang, E. Y. (2022) · Cancers · doi:10.3390/cancers14020416 · Cited by 174
“Histotypes are considered different diseases based on the cell of origin, molecular alterations, clinical behavior and management [1,2].”
BackgroundSelf-citationEpithelial–Mesenchymal Transition in Ovarian Carcinoma
Davidson, B., Tropé, C. G., & Reich, R. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00033 · Cited by 173
“Upregulation of Snail and MMP-2, with reduced E-cadherin level, was observed in ovarian carcinoma cells treated with 17β-Estradiol (Ding et al., 2006), with similar results reported for both Snail and Slug in another study (Park et al., 2008a).”
BackgroundResultInfluentialStoyanova, T., Goldstein, A. S., Cai, H., Drake, J. M., Huang, J., & Witte, O. N. (2012) · Genes & Development · doi:10.1101/gad.196451.112 · Cited by 149
“Trop2 is a type I transmembrane glycoprotein highly expressed in various epithelial cancers, such as advanced squamous cell carcinoma of the oral cavity and colorectal, pancreatic, gastric, and ovarian cancer, and its high levels correlate with poor prognosis and survival (Nakashima et al. 2004; Ohmachi et al. 2006; F…”
BackgroundTubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies
Sieh, W., Salvador, S., McGuire, V., Weber, R. P., Terry, K. L., Rossing, M. A., Risch, H., Wu, A. H., Webb, P. M., Moysich, K., et al. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt042 · Cited by 170
Self-citationThe biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas
Köbel, M., Reuss, A., Bois, A. D., Kommoss, S., Kommoss, F., Gao, D., Kalloger, S. E., Huntsman, D. G., & Gilks, C. B. (2010) · The Journal of Pathology · doi:10.1002/path.2744 · Cited by 170
Self-citationThe Changing View of High-Grade Serous Ovarian Cancer
Berns, E. M. J. J., & Bowtell, D. D. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3911 · Cited by 169
Precursors and pathogenesis of ovarian carcinoma
Lim, D. Y., & Oliva, E. (2013) · Pathology · doi:10.1097/pat.0b013e32835f2264 · Cited by 166
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary
Okamoto, A., Glasspool, R. M., Mabuchi, S., Matsumura, N., Nomura, H., Itamochi, H., Takano, M., Takano, T., Susumu, N., Aoki, D., et al. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000289 · Cited by 164
“Unlike HGS tumors, CCCs are generally p53 wild type and have a lower frequency ofBRCA1 andBRCA2mutations.(10) The most frequent alterations are ARID1A and PIK3CA mutations.”
BackgroundMucinous carcinomas of the ovary and colorectum: different organ, same dilemma
Kelemen, L. E., & Köbel, M. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70058-4 · Cited by 162
Self-citationShen, H., Fridley, B. L., Song, H., Lawrenson, K., Cunningham, J. M., Ramus, S. J., Cicek, M. S., Tyrer, J., Stram, D., Larson, M. C., et al. (2013) · Nature Communications · doi:10.1038/ncomms2629 · Cited by 160
Self-citationEstrogen Biosynthesis and Action in Ovarian Cancer
Mungenast, F., & Thalhammer, T. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00192 · Cited by 158
Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible: A Transcanadian Study
Köbel, M., Kalloger, S. E., Baker, P. M., Ewanowich, C. A., Arseneau, J., Zherebitskiy, V., Abdulkarim, S., Leung, S., Duggan, M. A., Fontaine, D., et al. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181e1a3bb · Cited by 149
“5-20) High-grade serous 76 5 15 80 4 56 50 25 80 22 (4-70) Clear cell 11 82 17 33 7 5 6 25 3 8 (1-27) Endometrioid 77 8 58 26 18 6 10 61 3 8 (1-49) Mucinous 6 7 15 0 73 0 10 7 0 13 (2-61)”
Self-citationValue of PAX 8 Immunostaining in Tumor Diagnosis: A Review and Update
Ordóǹez, N. G. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e318253465d · Cited by 154
The Origin of Ovarian Carcinomas: A Unifying Hypothesis
Auersperg, N. (2010) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3181f45f3e · Cited by 150
“morphologic phenotypes, genetic markers, and clinical courses (3,4).”
BackgroundSubtype‐specific mutation of PPP2R1A in endometrial and ovarian carcinomas
McConechy, M. K., Anglesio, M. S., Kalloger, S. E., Yang, W., Senz, J., Chow, C., Heravi‐Moussavi, A., Morin, G. B., Mes‐Masson, A., Australian Ovarian Cancer Study Group, et al. (2011) · The Journal of Pathology · doi:10.1002/path.2848 · Cited by 132
Self-citationEndometriosis-associated ovarian neoplasia
Matías‐Guiu, X., & Stewart, C. J. R. (2017) · Pathology · doi:10.1016/j.pathol.2017.10.006 · Cited by 145
“However, numerous pathological and molecular studies have demonstrated that the vast majority of these tumours are in fact HGSCs.35,36 Interestingly, a pseudoendometrioid pattern in HGSC is one of the histological features that characterises tumours with germline or somatic BRCA-1 mutations.37 Occasionally, a solid gr…”
BackgroundSynthesis of diagnostic quality cancer pathology images by generative adversarial networks
Levine, A. B., Peng, J., Farnell, D., Nursey, M., Wang, Y., Naso, J. R., Ren, H., Farahani, H., Chen, C., Chiu, D., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5509 · Cited by 120
“36,37 The fact that the synthetic images could be reliably classified supports our assertion that they are of diagnostic quality, which in our view implies that they are usable for directly clinically relevant tasks.”
BackgroundSelf-citationImmunity and Immune Suppression in Human Ovarian Cancer
Preston, C. C., Goode, E. L., Hartmann, L. C., Kalli, K. R., & Knutson, K. L. (2011) · Immunotherapy · doi:10.2217/imt.11.20 · Cited by 144
Bignotti, E., Todeschini, P., Calza, S., Falchetti, M., Ravanini, M., Tassi, R. A., Ravaggi, A., Bandiera, E., Romani, C., Zanotti, L., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.019 · Cited by 143
Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer: Utility of a Histology-Based Referral Strategy
Schrader, K. A., Hurlburt, J., Kalloger, S. E., Hansford, S., Young, S. S., Huntsman, D. D., Gilks, C. B., & McAlpine, J. N. (2012) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31825f3576 · Cited by 143
Self-citationLi, H., Cai, Q., Godwin, A. K., & Zhang, R. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0398 · Cited by 130
“(43) suggests that differences in Ki67 index among different subtypes of EOCs confound the Ki67 survival analysis because nearly all high-grade serous EOCs have a high Ki67 index.”
BackgroundKöbel, M., Bak, J., Bertelsen, B. I., Carpén, O., Grove, A., Hansen, E. S., Jakobsen, A. L., Lidang, M., Måsbäck, A., Tolf, A., et al. (2013) · Histopathology · doi:10.1111/his.12349 · Cited by 141
“The increased understanding of the biology of these tumours has led to the identification of biomarkers for different tumour types.(16,17) The ubiquitous presence of TP53 mutations in high-grade serous carcinomas and refined criteria for the interpretation of TP53 (p53) immunohistochemistry mean that TP53 can now be u…”
BackgroundSelf-citationCharacteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers
Page, C. L., Rahimi, K., Köbel, M., Tonin, P. N., Meunier, L., Portelance, L., Bernard, M., Nelson, B. H., Bernardini, M. Q., Bartlett, J. M. S., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4242-8 · Cited by 140
“Only CCC showed a significantly lower response to treatment compared to type other histotypes (OR = 2.73 (95%CI 1.42–5.26), p = 0.003).”
BackgroundResultInfluentialSelf-citationMulti-biomarker panel signature as the key to diagnosis of ovarian cancer
Muinao, T., Boruah, H. P. D., & Pal, M. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02826 · Cited by 138
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer
Saux, O. L., Ray-Coquard, I. L., & Labidi‐Galy, S. I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.017 · Cited by 138
High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression
Roh, M. H., Yassin, Y., Miron, A., Mehra, K. K., Mehrad, M., Monte, N. M., Mutter, G. L., Nucci, M. R., Ning, G., McKeon, F., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.119 · Cited by 137
Köbel, M., Kalloger, S. E., Santos, J. L., Huntsman, D. D., Gilks, C. B., & Swenerton, K. D. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.029 · Cited by 133
“Tumor type is now appreciated to reflect different diseases, with type-specific risk factors, precursor lesions, molecular events during oncogenesis, biomarker expression, clinical behavior and response to chemotherapy [12,13].”
BackgroundSelf-citationApplication of Immunohistochemistry in Thyroid Pathology
Liu, H., & Lin, F. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0056-ra · Cited by 131
“de Micco et al,(168) 2008 80 0/59 (0) 0/32 (0) 39/54 (72) 51/55 (93) Savin et al,(169) 2006 80 11/52 (21) 24/40 (60)”
Qi, X., Zhang, F., Wu, H., Liu, J., Zong, B., Xu, C. S., & Jiang, J. (2015) · Scientific Reports · doi:10.1038/srep08924 · Cited by 129
Kim, T. H., Kim, Y. K., Kwon, Y., Heo, J. H., Kang, H., Kim, G., & An, H. J. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03686.x · Cited by 123
Applications of Proteomics in Ovarian Cancer: Dawn of a New Era
Ghose, A., Gullapalli, S. V. N., Chohan, N., Bolina, A., Moschetta, M., Rassy, E., & Boussios, S. (2022) · Proteomes · doi:10.3390/proteomes10020016 · Cited by 127
Ovarian low-grade serous carcinoma: A comprehensive update
Díaz-Padilla, I., Malpica, A. L., Minig, L., Chiva, L. M., Gershenson, D. M., & González-Martín, A. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.04.029 · Cited by 126
“It comprises though a heterogeneous group of tumors with distinctly different histological characteristics, molecular features, and clinical behavior [2–5].”
BackgroundTGF-β isoforms induce EMT independent migration of ovarian cancer cells
Gao, J., Zhu, Y., Nilsson, M., & Sundfeldt, K. (2014) · Cancer Cell International · doi:10.1186/s12935-014-0072-1 · Cited by 124
“Complete EMT has also been described after TGF-β treatment in clearcell ovarian cancer, another ovarian cancer histologic sub-type [5,6,25].”
BackgroundROR1 expression correlated with poor clinical outcome in human ovarian cancer
Zhang, H., Qiu, J., Ye, C., Yang, D., Gao, L.-J., Su, Y., Tang, X., Xu, N., Zhang, D., Xiong, L., et al. (2014) · Scientific Reports · doi:10.1038/srep05811 · Cited by 122
Cowin, P. A., George, J., Fereday, S., Loehrer, E., Van Loo, P., Cullinane, C., Etemadmoghadam, D., Ftouni, S., Galletta, L., Anglesio, M. S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0203 · Cited by 109
“HGSC show considerable DNA copy number change (19), with high rates of genomic instability (20) and somatic TP53mutation (21, 22).”
BackgroundOvarian cancer risk factors by histologic subtypes in the NIH‐AARP diet and health study
Yang, H. P., Trabert, B., Murphy, M. A., Sherman, M. E., Sampson, J. N., Brinton, L. A., Hartge, P., Hollenbeck, A., Park, Y., & Wentzensen, N. (2012) · International Journal of Cancer · doi:10.1002/ijc.26469 · Cited by 112
Dinh, H. Q., Lin, X., Abbasi, F., Nameki, R. A., Haro, M., Olingy, C. E., Chang, H. S. Y., Hernández, L., Gayther, S. A., Wright, K. N., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108978 · Cited by 118
AOCS Study Group, Köbel, M., Madore, J., Ramus, S. J., Clarke, B. A., Pharoah, P. D. P., Deen, S., Bowtell, D. D. L., Odunsi, K. O., Menon, U., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.567 · Cited by 118
“These two studies contained a mixture of all histological types, which may mask associations when both the marker prevalence (Kalli et al, 2008) and survival rates (Kobel et al, 2008) differ between the histological types.”
BackgroundSelf-citationModest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
de Graeff, P., Crijns, A. P. G., de Jong, S., Boezen, M., Post, W. J., de Vries, E. G. E., van der Zee, A. G. J., & de Bock, G. H. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605112 · Cited by 115
“…Graeff et al, 2006; Brustmann, 2007; Galic et al, 2007; Malamou-Mitsi et al, 2007; Materna et al, 2007; Psyrri et al, 2007; Bartel et al, 2008; Darcy et al, 2008; Garcia-Velasco et al, 2008; Giordano et al, 2008; Kobel et al, 2008; Leffers et al, 2008; Tomsova et al, 2008; Vartiainen et al, 2008).”
BackgroundMethodInfluentialHughes, C. S., McConechy, M. K., Cochrane, D. R., Nazeran, T., Karnezis, A. N., Huntsman, D. G., & Morin, G. B. (2016) · Scientific Reports · doi:10.1038/srep34949 · Cited by 112
Self-citationRambau, P., Vierkant, R. A., Intermaggio, M. P., Kelemen, L. E., Goodman, M. T., Herpel, E., Pharoah, P. D. P., Kommoss, S., Jimenez‐Liñan, M., Karlan, B. Y., et al. (2018) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.109 · Cited by 113
“Overall, those histotypespecific differences would not have been revealed in a combined histotype analysis and corroborate that biomarker analyses should be done stratified by histotype [12].”
BackgroundSelf-citationO'Shannessy, D. J., Somers, E. B., Smale, R., & Fu, Y. (2013) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3182774562 · Cited by 113
Metadata
- Authors
- Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., Prentice, L. M., Miller, D., Santos, J., Swenerton, K., Gilks, C. B., & Huntsman, D.
- Affiliations
- BC Cancer Agency (CA)
- Canary Foundation (US)
- Georgia Institute of Technology (US)
- Corresponding author
- Huntsman, David
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 5
- Issue
- 12
- Pages
- e232
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2592352
- OpenAlex
- W2129355295
- Cited by
- 814
- References
- 40
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 30 · 2023: 43 · 2022: 34 · 2021: 37 · 2020: 39 · 2019: 33 · 2018: 50 · 2017: 44 · 2016: 60 · 2015: 42 · 2014: 60 · 2013: 71 · 2012: 70
- FWCI
- 59.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Sanofi
- Canary Foundation
- Michael Smith Health Research BC
- Eli Lilly Canada
- Canadian Institutes of Health Research (017051)
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- ovarian carcinoma, histological subtypes, high-grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, tumor markers, prognostic factors, Ki-67, WT1, CA125, HE4, stage at diagnosis, survival, molecular pathogenesis, tumor cell proliferation
- MeSH terms
- Carcinoma, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Ovarian Diseases, Ovarian Neoplasms, Prognosis, Retrospective Studies, Biomarkers, Tumor, Cohort Studies, Confounding Factors, Epidemiologic, Survival Analysis, Tissue Array Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.